EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Loss in Overall and Quality‐Adjusted Life Expectancy for Patients With Chronic‐Phase Chronic Myeloid Leukemia

Enoch Yi-Tung Chen iD, Torsten Dahlén iD, Leif Stenke, Magnus Björkholm, Shuang Hao, Paul W Dickman, Mark S Clements

European Journal of Haematology · 2025-02 · 114 (2) · 334-342

DOI: 10.1111/ejh.14328 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 06.11.2024. Verfasst von Enoch Yi-Tung Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Quality-Adjusted Life Years, Life Expectancy, Leukemia, Myeloid, Chronic-Phase. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Vetenskapsrådet, Cancerfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The introduction of tyrosine kinase inhibitors has considerably improved the life expectancy (LE) for patients with chronic myeloid leukemia (CML). Evaluating health‐related quality of life within the treatment pathway remains crucial. Using the Swedish CML register, we included 991 adult patients with chronic‐phase (CP) CML diagnosed 2007 to 2017, with follow‐up until 2018. We developed a multistate model to estimate the loss in LE (LLE) and loss in quality‐adjusted life expectancy (LQALE) for the patient population compared to the general population, along with the respective proportions of losses relative to the general population. All patients with CP‐CML had a relatively low reduced LE but with larger LQALE. The maximum LLE within age/sex subgroups was 5.7 years (general population LE: 43.2 years vs. CP‐CML LE: 37.5 years) for females diagnosed at age 45 years, with LQALE of 12.0 quality‐adjusted life years (QALYs) (general population QALE: 38.2 QALYs vs. CP‐CML QALE: 26.3 QALYs). Across all ages, the proportions of LLE ranged from 9% to 15%, and the proportions of LQALE were 29% to 33%. Despite a low LLE, our findings reveal a greater LQALE for patients with CP‐CML. Further improvements in management of CP‐CML are thus warranted to successfully address the prevailing medical needs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality-Adjusted Life YearsLife ExpectancyLeukemia, Myeloid, Chronic-PhaseHumansFemaleMaleMiddle AgedAdultAgedSwedenQuality of LifeRegistriesYoung AdultAged, 80 and overAdolescent

Stichwörter der Autor:innen

chronic myeloid leukemiahealth‐related quality of lifelife expectancyquality‐adjusted life yearsreal‐world evidence

Autor:innen und Institutionen

  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden.
  • Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden.
  • Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: Enoch Yi-Tung Chen, Torsten Dahlén

Förderung

  • Vetenskapsrådet
  • Cancerfonden

Zitieren

APA

Chen, E. Y., Dahlén, T., Stenke, L., Björkholm, M., Hao, S., Dickman, P. W., & Clements, M. S. (2025). Loss in Overall and Quality‐Adjusted Life Expectancy for Patients With Chronic‐Phase Chronic Myeloid Leukemia. European Journal of Haematology, 114(2), 334-342. https://doi.org/10.1111/ejh.14328

Vancouver

Chen EY, Dahlén T, Stenke L, Björkholm M, Hao S, Dickman PW, et al. Loss in Overall and Quality‐Adjusted Life Expectancy for Patients With Chronic‐Phase Chronic Myeloid Leukemia. European Journal of Haematology. 2025;114(2):334-342. doi:10.1111/ejh.14328

BibTeX
@article{Chen2025,
  author = {Chen, Enoch Yi-Tung and Dahlén, Torsten and Stenke, Leif and Björkholm, Magnus and Hao, Shuang and Dickman, Paul W and Clements, Mark S},
  title = {Loss in Overall and Quality‐Adjusted Life Expectancy for Patients With Chronic‐Phase Chronic Myeloid Leukemia},
  journal = {European Journal of Haematology},
  year = {2025},
  volume = {114},
  number = {2},
  pages = {334--342},
  doi = {10.1111/ejh.14328}
}
Kostenlos starten →